Inter J Stomatol ›› 2018, Vol. 45 ›› Issue (2): 140-144.doi: 10.7518/gjkq.2018.02.004
• Oral Medicine • Previous Articles Next Articles
Xiao Yandi, Yang Huamei, Dan Hongxia
CLC Number:
[1] Common terminology criteria for adverse events (CTCAE) version 4.0[S]. Bethesda: National Insti-tutes of Health, National Cancer Institute, 2009. [2] Vigarios E, Epstein JB, Sibaud V.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors[J]. Support Care Can-cer, 2017, 25(5):1713-1739. [3] Yuan A, Woo SB.Adverse drug events in the oral cavity[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2015, 119(1):35-47. [4] Shameem R, Lacouture M, Wu S.Incidence and risk of high-grade stomatitis with mTOR inhibitors in can-cer patients[J]. Cancer Invest, 2015, 33(3):70-77. [5] Vargo CA, Berger MJ, Phillips G, et al.Occurrence and characterization of everolimus adverse events during first and subsequent cycles in the treatment of metastatic breast cancer[J]. Support Care Cancer, 2016, 24(7):2913-2918. [6] Rugo HS, Hortobagyi GN, Yao J, et al.Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy[J]. Ann Oncol, 2016, 27(3):519-525. [7] Kaplan B, Qazi Y, Wellen JR.Strategies for the ma-nagement of adverse events associated with mTOR inhibitors[J]. Transplant Rev (Orlando), 2014, 28(3): 126-133. [8] Soria JC, Felip E, Cobo M, et al.Afatinib versus erlo-tinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial[J]. Lancet Oncol, 2015, 16(8):897-907. [9] Park K, Tan EH, O’Byrne K, et al. Afatinib versus ge-fitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial[J]. Lancet Oncol, 2016, 17(5):577-589. [10] Burotto M, Manasanch EE, Wilkerson J, et al.Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials[J]. Oncologist, 2015, 20(4):400-410. [11] Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma[J]. N Engl J Med, 2015, 373(19):1803-1813. [12] Yamany T, Levender M, Silvers DN, et al.Erythema multiforme-like reaction with mucosal involvement following administration of idelalisib for relapse of chronic lymphocytic leukemia[J]. Leuk Lymphoma, 2015, 56(6):1872-1873. [13] Edwards D, Boritz E, Cowen EW, et al.Erythema multiforme major following treatment with infliximab[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013, 115(2):e36-e40. [14] Lowndes S, Darby A, Mead G, et al.Stevens-Johnson syndrome after treatment with rituximab[J]. Ann Oncol, 2002, 13(12):1948-1950. [15] Peterson DE, O’Shaughnessy JA, Rugo HS, et al. Oral mucosal injury caused by mammalian target of rapa-mycin inhibitors: emerging perspectives on pathobio-logy and impact on clinical practice[J]. Cancer Med, 2016, 5(8):1897-1907. [16] Kuten-Shorrer M, Hochberg EP, Woo SB.Lichenoid mucosal reaction to rituximab[J]. Oncologist, 2014, 19(10):e12-e13. [17] Zhang JA, Yu JB, Li XH, et al.Oral and cutaneous lichenoid eruption with nail changes due to imatinib treatment in a chinese patient with chronic myeloid leukemia[J]. Ann Dermatol, 2015, 27(2):228-229. [18] Luo JR, Xiang XJ, Xiong JP.Lichenoid drug eruption caused by imatinib mesylate in a Chinese patient with gastrointestinal stromal tumor[J]. Int J Clin Pharmacol Ther, 2016, 54(9):719-722. [19] Bloom MD, Gibney JM, Heldermon CD.Pigmentation of the tongue with lapatinib treatment in a patient with advanced breast cancer: a case report[J]. Cancer Treat Commun, 2016, 7:1-3. [20] Khoo TL, Catalano A, Supple S, et al.Hyperpigmen-tation of the hard palate associated with imatinib the-rapy for chronic myeloid leukemia with a genetic va-riation in the proto-oncogene c-KIT[J]. Leuk Lym-phoma, 2013, 54(1):186-188. [21] Li CC, Malik SM, Blaeser BF, et al.Mucosal pigmenta-tion caused by imatinib: report of three cases[J]. Head Neck Pathol, 2012, 6(2):290-295. [22] Ellis PM, Shepherd FA, Millward M, et al.Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial[J]. Lancet Oncol, 2014, 15(12):1379-1388. [23] Rizvi NA, Mazières J, Planchard D, et al.Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squa-mous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial[J]. Lancet Oncol, 2015, 16(3):257-265. [24] Robert C, Schachter J, Long GV, et al.Pembrolizumab versus ipilimumab in advanced melanoma[J]. N Engl J Med, 2015, 372(26):2521-2532. [25] Boer CC, Correa ME, Miranda EC, et al.Taste dis-orders and oral evaluation in patients undergoing allo-geneic hematopoietic SCT[J]. Bone Marrow Transplant, 2010, 45(4):705-711. [26] Robert C, Long GV, Brady B, et al.Nivolumab in previously untreated melanoma without BRAF muta-tion[J]. N Engl J Med, 2015, 372(4):320-330. [27] Tang N, Ratner D.Managing cutaneous side effects from targeted molecular inhibitors for melanoma and nonmelanoma skin cancer[J]. Dermatol Surg, 2016, 42(Suppl 1):S40-S48. [28] Gavrilovic IT, Balagula Y, Rosen AC, et al.Charac-teristics of oral mucosal events related to bevacizu-mab treatment[J]. Oncologist, 2012, 17(2):274-278. [29] Hubiche T, Valenza B, Chevreau C, et al.Geographic tongue induced by angiogenesis inhibitors[J]. Oncologist, 2013, 18(4):e16-e17. [30] Rosen AC, Gavrilovic IT, Balagula Y, et al.In reply[J]. Oncologist, 2013, 18(4):e18. |
[1] | Pan Jian, Zhang Zhuang.. Complications of oral local anesthesia and their preventive treatments [J]. Inter J Stomatol, 2012, 39(2): 141-144. |
[2] | Chen Zhe1, Wang Jing2, Wang Hu3.. The music therapy in the field of oral treatment [J]. Inter J Stomatol, 2011, 38(6): 734-737. |
[3] | ZHAO Fang, LIU Dong-xu. Application of functional magnetic resonance imaging in stomatology [J]. Inter J Stomatol, 2009, 36(5): 586-589. |